1420 (100) Anthracycline only 136 (10) 135 (10) Anthracycline plus taxane 962 (68) 965 (68) Taxane only 318 (22) 316 ( b Stratification factor collected from the interactive voice-and web-response system. For nodal status, the number of positive nodes was recorded at the time of initial diagnosis (for those who received adjuvant therapy) or surgery (for those who received neoadjuvant therapy). Patients with residual invasive disease in the breast but node negative or unknown nodal status in the axilla after neoadjuvant therapy were included under "1-3" positive nodes.
c Percentage is based on the number of patients with hormone receptor-positive disease. Tumors were assessed as being ER or PR positive based on local pathology laboratory cut-offs. There was no protocol specification as to whether a 1% or 10% threshold should be used.
d Proportion of patients who received neoadjuvant chemotherapy in the neratinib group was 25% and in the placebo group it was 27%. Median (IQR) treatment duration, months 11.7 (5.1-12.0) 11.8 (11.5-12.0)
Supplementary
Mean (SD) relative dose intensity, % 96 (10) 98 (5) Dose reduction, N (%) 52 (13) 96 (7) Dose hold, N (%) 154 (40) 554 (43) Grade 2 diarrhea, N 458 94
Median (IQR) treatment duration, months 11.7 (3.2-12.0) 11.9 (11.5-12.0)
Mean (SD) relative dose intensity, % 90 (15) 97 (5) Dose reduction, N (%) 150 (33) 11 (12) Dose hold, N (%) 278 (61) 55 (59) Grade 3 diarrhea, N 561 23
Median (IQR) treatment duration, months 11.5 (1.3-11.9) 11.6 (11.0-11.9)
Mean (SD) relative dose intensity, % 80 (21) 96 (7) Dose reduction, N (%) 317 (57) 2 (22) Dose hold, N (%) 417 (74) 14 (61) IQR, interquartile range; SD, standard deviation.
a In the neratinib group, 1 patient with grade 4 diarrhea was excluded.
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